Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability